Injectable polyethylene glycol-fibrinogen hydrogel adjuvant improves survival and differentiation of transplanted mesoangioblasts in acute and chronic skeletal-muscle degeneration

Cell-transplantation therapies have attracted attention as treatments for skeletal-muscle disorders; however, such research has been severely limited by poor cell survival. Tissue engineering offers a potential solution to this problem by providing biomaterial adjuvants that improve survival and engraftment of donor cells.

Methods: In this study, we investigated the use of intra-muscular transplantation of mesoangioblasts (vessel-associated progenitor cells), delivered with an injectable hydrogel biomaterial directly into the tibialis anterior (TA) muscle of acutely injured or dystrophic mice.

The hydrogel cell carrier, made from a polyethylene glycol-fibrinogen (PF) matrix, is polymerized in situ together with mesoangioblasts to form a resorbable cellularized implant

Results: Mice treated with PF and mesoangioblasts showed enhanced cell engraftment asa result of increased survival and differentiation compared with the same cell population injected in aqueous saline solution.

Conclusion: Both PF and mesoangioblasts are currently undergoing separate clinical trials: their combined use may increase chances of efficacy for localized disorders of skeletal muscle.

Author: Claudia FuocoMaria Lavinia SalvatoriAntonella BiondoKeren Shapira-SchweitzerSabrina SantoleriStefania AntoniniSergio BernardiniFrancesco Saverio TedescoStefano CannataDror SeliktarGiulio CossuCesare Gargioli
Credits/Source: Skeletal Muscle 2012

Published on: 2012-11-26

Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.


Custom Search


© 2015 7thSpace Interactive
All Rights Reserved - About | Disclaimer | Helpdesk